

## DAFTAR PUSTAKA

1. WHO. Cancer. 2018.
2. Putriani FA, Kholis FN, Purwoko Y. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru dengan Mutasi EGFR dan NON Mutasi EGFR. 2019.
3. Hudoyo A, Wibawanto A, Lutfi A, Rima A, Putra AC, Ratnawati A, et al. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. Jakarta: Komite Penanggulangan Kanker Nasional; 2017.
4. FARMACIA. Mengoptimalkan Manajemen Kanker Paru. Metamorph; 2012.
5. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. *Oncol Rep*. 2000.
6. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD, et al. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. *Hum Pathol*. 2005.
7. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med*. 2009.
8. Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). *Lung Cancer*. 2019.
9. Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchu P, Kondo C, et al. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first or third generation TKIs. *aacrjournals*. 2015.
10. Roy WA. Sobotta Atlas of Anatomy: General Anatomy and Musculoskeletal System. *Phys Ther*. 2006.
11. L. Drake R, Vogl W, Mitchell AWM. Gray's Basic Anatomy. Elsevier. 2012
12. DiFiore's. Atlas of Histology with functional correlations . Vasa. 2008.
13. John E. Hall. Medical Physiology. Vol. 12, Guyton and Hall Textbook of

Medical Physiology. 2011.

14. Jayanti E. Evaluasi Penggunaan Kemoterapi pada Pasien Kanker Paru di Instalasi Rawat Inap RSUD Dr.Moewardi Tahun 2010-2011. Fak Farm Univ Muhammadiyah Surakarta. 2013.
15. Hariyanto W, Hasan H. Buku Ajar Ilmu Penyakit Dalam. Vol. 1, Interna Publishing. Jakarta Pusat; 2014.
16. Lukeman JM. What Is Lung Cancer ? 1977.
17. Dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2011.
18. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC eds. Pathology & Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC/Press. 2004
19. Society AC. About Non-Small Cell Lung Cancer. 2016.
20. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: Roadmap for therapies. Eur Respir J. 2009.
21. Aliyah N, Pranggono EH, Andriyoko B. Kanker Paru: Sebuah Kajian Singkat. Ina J CHEST Crit Emerg Med. 2016.
22. Willoughby JW. Harrison's Principles of Internal Medicine. 18th ed. Dan L. Longo, MD. Dennis L. Kasper, MD.J. Larry Jameson, MD, PhD.Anthony S. Fauci, MD.Stephen L. Hauser, MD.Joseph Loscalzo, MD P, editor. Mc Graw Hill
23. Li C, Lu H. Adenosquamous carcinoma of the lung. Onco Targets Ther. 2018.
24. Yang Z, Li H, Wang Z, Yang Y, Niu J, Liu Y, et al. Microarray expression profile of long non-coding RNAs in human lung adenocarcinoma. Thorac Cancer. 2018.
25. Oh IJ, Hur JY, Park CK, Kim YC, Kim SJ, Lee MK, et al. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. Clin Lung Cancer. 2018.
26. Rami-porta R, Call S, Doooms C, Obiols C, Sánchez M, Travis WD, et al. Lung cancer staging : a concise update.
27. Majmundar N, Shao B, Assina R. Lung adenocarcinoma presenting as

- intramedullary spinal cord metastasis : Case report and review of literature. *J Clin Neurosci*. 2018.
28. Erickson LA. Lung Adenocarcinoma. *Mayo Clin Proc*. 2018.
  29. Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the Epidermal Growth Factor Receptor Status in Lung Cancers Reflected in Clinicopathologic Features. 2010.
  30. Midha A, Dearden S, McCormack R. Original Article EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology : a systematic review and global map by ethnicity ( mutMapII ). 2015.
  31. Ladanyi M, Pao W. Lung adenocarcinoma : guiding EGFR-targeted therapy and beyond. 2008.
  32. Massarelli E, Varella-garcia M, Tang X, Massarelli E, Varella-garcia M, Tang X, et al. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non – Small-Cell Lung Cancer KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor. 2007.
  33. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Giovanni L, Bemis L, et al. Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non – Small-Cell Lung Cancer. 2005.
  34. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. 2002.
  35. Sandler A, Gray R, Ph D, Perry MC, Brahmer J, Schiller JH, et al. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. 2006.
  36. Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs Supportive Care in \* Advanced Non-Small-Cell Lung Cancer Results of a Meta-analysis of the Literature. 1994.
  37. Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, et al. EGFR Mutations in Lung Adenocarcinomas Clinical Testing Experience and Relationship to EGFR Gene. *J Mol Diagnostics*. 2008.
  38. Pas T De, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, et al. Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor. *J Thorac Oncol*. 2011.

39. Lee CK, Wu Y, Ding PN, Lord SJ, Inoue A, Zhou C, et al. Impact of Specific Epidermal Growth Factor Receptor ( EGFR ) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR -Mutant Lung Cancer : A Meta-Analysis. 2015.
40. Arrieta O, Felipe A, Corrales L, Campos-parra AD, Sánchez-reyes R, Amieva-rivera E, et al. Lung Cancer The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. 2015.
41. Yoon H, Id JR, Sim YS, Kim D, Id HC. Clinical significance of EGFR mutation types in lung adenocarcinoma : A multi-centre Korean study. 2020.
42. Nie Y, Gao W, Li N, Chen W, Wang H, Li C, et al. Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma. 2017.
43. Adenocarcinoma L. Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I. 2015.
44. Beypinar I, Demir H, Araz M, Uysal M. The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma. J Oncol Sci. 2019.
45. Zhou X, Cai LI, Liu J, Hua X, Zhang Y. Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma. 2018.
46. Hsu F, Caluwe A De, Anderson D, Nichol A, Toriumi T, Ho C. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. 2017.
47. Sekine A, Kato T, Hagiwara E, Shinohara T, Komagata T. Lung Cancer Metastatic brain tumors from non-small cell lung cancer with EGFR mutations : Distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer. 2012.
48. Zhang Y, Sheng J, Kang S, Fang W, Yan Y, Hu Z, et al. Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer : A Meta-Analysis. 2014.
49. Sutiman N, Tan SW, Tan EH, Lim WT. EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced Asian

NSCLC patients. J Thorac Oncol. 2016.

